This email address is being protected from spambots. You need JavaScript enabled to view it.

  • Home
  • The network
  • Contributing sites

Contributing sites

20+ participating SITES (NH & SH)
in the 2019-2020 & 2020-2021 season

map gihsn home


Implementing Partners

Hôpital Cochin (France, Paris)

2019-2020 & 2020-2021

Since 2011, CIC Cochin Pasteur is involved into the vaccine effectiveness studies, including FluVac, conducted within the framework of a European surveillance network (I-MOVE) and GIHSN.

The primary objective of these studies is to evaluate the seasonal influenza vaccine effectiveness against hospitalized flu in adults. The secondary objectives are to describe the epidemiology of hospital admissions with influenza and the impact of underlying patient characteristics on the risk of admission and complications related to infection with A(H1N1)pdm09, A(H3N2) and both influenza B lineages, during flu seasons.

The studies are focused on the adult patient (>18 y/o). Influenza B samples confirmed are sent to the National Influenza Reference Centre (Prof. Bruno Lina, CNR-Lyon) to realise the lineage of Yamagata and Victoria.

Professor Odile Launay, Principal Investigator

Hôpital Cochin

partners kenya

Kenya Medical Research Institute (KEMRI) and US Centers for Disease Control and Prevention (CDC) Research Collaboration (Nairobi, Kenya)

2019-2020 & 2020-2021

Kenya has conducted surveillance for influenza since 2006. Published data from these surveillance activities have shown a substantial burden of influenza, especially among children aged less than five years.

The GIHSN study is conducted using the existing health and demographic surveillance system (HDSS) in Western Kenya to estimate the incidence of influenza- and respiratory syncytial virus (RSV) - associated hospitalizations, and to quantify the distribution of the different influenza strains circulating in Kenya.

Data collected from this study will help bridge the gap on the burden of disease data in Kenya, particularly among the elderly as recently requested by the Kenya National Immunization Technical Advisory Group.

Dr. Gideon O. Emukule

• Siaya County Referral Hospital
• Lwak Mission Hospital

partners canada

Canadian Center for Vaccinology (Halifax, Canada)

2019-2020 & 2020-2021

The Canadian Center for Vaccinology (CCfV) is a multidisciplinary vaccinology research centre of Dalhousie University developed with funding from the Canada Foundation for Innovation, which brings together investigators from adult and pediatric infectious diseases, internal medicine, geriatrics, health law and bioethics, public health, nursing, pharmacy, epidemiology, health outcomes and health economics. CCfV is the lead institution and coordinating center for the Canadian Immunization Research Network. The SOS Network is coordinated by the Canadian Center for Vaccinology in Halifax, Nova Scotia.

Professor Shelly McNeil

partners spain

The Foundation for the Promotion of Health and Biomedical Research of Valencia Region “FISABIO” (Valencia, Spain)

2019-2020 & 2020-2021

The Foundation for the Promotion of Health and Biomedical Research of Valencia Region, FISABIO, is a non-profit scientific and healthcare entity, whose primary purpose is to encourage, to promote and to develop scientific and technical health and biomedical research in Valencia Region.

FISABIO integrates and manages the Health Research Map of the Centre for Public Health Research, Dr. Peset University Hospital Foundation, Alicante University General Hospital Foundation, Elche University General Hospital Foundation, and the Mediterranean Ophthalmological Foundation. In addition, FISABIO assumes the scientific activity of other 18 Health Departments.

Javier Díez-Domingo, Head of Area

• Hospital General, Castellòn
• Hospital La Fe, Valencia
• Hospital Dr Peset, Valencia
• Hospital General, Alicante

partners southafrica

Respiratory and Meningeal Pathogens Research Unit (South Africa)

2019-2020 & 2020-2021

RMPRU is a research Unit focused on the epidemiology, transmission, prevention and diagnosis of vaccine preventable diseases. RMPRU forms part of and is administered by the Wits Health Consortium, a wholly owned subsidiary of the University of the Witwatersrand.

RMPRU was established in 1997, with an original research mandate to investigate pneumococcal diseases at the molecular, epidemiological, clinical and pharmacological levels. Over time, the Unit has evolved to include investigating the clinical and molecular epidemiology of other bacteria and respiratory viruses that are associated with pneumonia and meningitis. Also, the Unit has established itself to be a premier clinical trial facility for vaccine and training platforms for post-graduate students.

The Unit has undertaken pivotal studies on pneumococcal conjugate vaccine, which have helped inform the utilisation of these vaccines in low-to-middle income countries. Also, the pneumococcal vaccine studies have helped inform the interaction of pneumococcus in relation to respiratory viruses and tuberculosis associated acute community acquired pneumonia. More recently, the Unit has further evolved to focus specifically on the epidemiology and prevention of infections during the neonatal period, including programs aimed at vaccinating pregnant women to confer passive immunity and protect infants during their first few months of life. These include studies on the influenza vaccines, GBS conjugate vaccine, pertussis vaccine and RSV vaccines.

• Marta Nunes
• Shabir Madhi

Chris Hani Baragwanath Academic Hospital, Soweto, South Africa

partners india

Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Department of Internal and Pulmonary Medicine (India)

2019-2020 & 2020-2021

The SKIMS is engaged to provide high quality patient care, academic courses and need-based biomedical research to provide better patient care.

The institute has been one of the sites of the CDC,USA sponsored Multisite Surveillance for Influenza across India that has documented the patterns of influenza circulation in India.

Parvaiz A KOUL

Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar

partners china

Fudan University (Shanghai, China)

2019-2020 & 2020-2021

The study team is composed by the School of Public Health, Fudan University (SPH), Soochow University Affiliated Children’s Hospital (SCH) and Suzhou Center for Disease Control and Prevention (CDC).

All three institutions are well coordinated since foundation by US CDC in March 2011.
Fudan University is a comprehensive research university in China. As one of the first participants in the 211 and 985 projects. Fudan has 28 schools and 11 affiliated hospitals.

Since Mar 2011, founded by US CDC, the influenza surveillance system was established in Soochow University Affiliated Children’s Hospital (SCH). The surveillance includes influenza-like illness (ILI) and severe acute respiratory infection (SARI) patients.

SCH is a comprehensive tertiary hospital for children, one of the national influenza monitoring network hospitals, integrated with medical treatment, teaching, research and preventive health care.

Dr.Tao Zhang, the Principal Investigator and Coordinator

Soochow University Affiliated Children’s Hospital

partners russia

Ivanovsky Institute of Virology FSBI “Federal Research Center of Microbiology and Epidemiology named after N.F. Gamaleya”, Ministry of Healthcare of the Russian Federation, WHO National Influenza Cent (Russia)

2019-2020 & 2020-2021

D.I. Ivanovsky Institute of Virology is one of the first-rate research organizations in the field of ecology, epidemiology, molecular biology, and molecular virology. Its mission is fundamental researching of virology, development and improvement of diagnostic methods and assessment of new antivirals against highly infectious and social diseases. Institute has been involved in influenza surveillance since 1959 both in Russia (USSR) and WHO. Since 2014 Institute had became a part of FSBI “N.F. Gamaleya FRCEM”.

Web site (in Russian)

Elena BURTSEVA, Head of Influenza Etiology and Epidemiology laboratory

• Clinical Hospital for Infectious Diseases n°1 (CHID), Moscow
• Hospital specializes on virus infectious diseases mainly, which are caused by influenza and non-influenza respiratory viruses, enteroviruses, hepatitis B and C, rotavirus, AIDS and etc. Hospital has the wards for pregnants and beds in intensive unit care (IUC).

partners stpetersburg

Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, WHO recognized National Influenza Centre (Saint Petersburg) (Russia)

2019-2020 & 2020-2021

RII is a leading institution in the field of influenza and ARI surveillance in Russia.

RII incorporates Federal Influenza and ARI Centre and WHO National Influenza Centre, successfully operating both on the national and global levels as an integral part of WHO global influenza surveillance and response system.


• Clinical Infectious Diseases Hospital, Saint Petersburg
• Children's Infectious Multidisciplinary Hospital #5, Saint Petersburg
• Children's Multidisciplinary Hospital #4, Saint Petersburg

partners mexico

Mexico National Institutes of Health and High Speciality Hospitals Surveillance Network (Mexico)

2019-2020 & 2020-2021

The Ministry of Health Coordination Center of the National Institutes of Health and High Speciality Hospital (CCINSHAE)'s mission is to promote the highest level of scientific knowledge and to develop, maintain, and renew scientific human and physical resources that will ensure the Nation's capability to prevent disease, enhance health and reduce illness and disability.

The Mexico National Institutes of Health and High Specialty Hospitals Surveillance Network integrate 12 National Health Institutions and Hospitals to ensure a wide geographic representation of the north, central and south areas of the country. Its purpose is the timely identification and estimation of the incidence of severe illness (hospitalization) and the description of the clinical characteristics caused by influenza and other respiratory viruses, as well as new and emerging infectious treats to ultimately protect and improve the health of the individual and the allocation of economic resources.

Dr Guillermo M. Ruiz Palacios, MD, FIDSA, Director National Institutes of Health and High Speciality Hospitals, Ministry of Health, Mexico

• Instituto Nacional de Ciencias médicas y Nutrición Salvador Zubirán
• Instituto Nacional de Enfermedades Respiratorias (INER)
• Instituto Nacional de pediatría (INP)
• Hospital Infantil de México (HIM)
• Hospital General Dr. Manuel Gea González
• Hospital Central Dr. Ignacio Morones Prieto (San Luis Potosí)

partners peru

Tropical Medicine Institute Daniel A. Carrion, San Marcos University, Lima – Peru and Centro de Investigaciones Tecnológicas, Biomédica y Medioambientales CITBM (Peru)

2019-2020 & 2020-2021

The Tropical Medicine Institute Daniel Carrion´s mision is to promote a highest level of scientific knolewdge in Tropical Infectious Diseases to contribute in the health care of the peruvian population. This Tropical Institute (IMT DAC in Spanish)works closely with the CITBM under a collaborative agreementincluding associate business and international research activities.

CITBM is the first Center of Excellence in Peru dedicated to the integration of science, development and technological innovation. CITBM is collaborating in multiple national and multinational biomedical, technology and innovation projects, including the development of rapid diagnostic tests and vaccines for infectious tropical diseases as malaria, leptospirosis, leishmaniasis and meningeal tuberculosis. Additionally, it leads the international consortium MDRTBNet (aERANet Lac initiative), with reference institutes of tuberculosis in Germany, Spain, France, Brazil and Italy.

Victor Alberto Laguna-Torres. MTMH. PhD Infectious diseases physician. Principal Investigator

• Hospital Nacional 2 de Mayo, Ministerio de Salud del Perú, Lima Perú
• Clínica Internacional, Lima Perú
• Hospital San Rosa, Ministerio de Salud, Piura, Perú

partners romania

The National Institute for Infectious Diseases “Prof. Dr. Matei Bals” (Romania)

2019-2020 & 2020-2021

The National Institute for Infectious Diseases “Prof. Dr. Matei Bals” is the excellence center in Romania for prevention, management and research in area of infectious diseases. As a research center, the hospital has extensive experience in conducting clinical trials in the field of infectious diseases having a dedicated and accredited (FDA) clinical trials center. Vaccine trials were routinely conducted in National Institute of Infectious Diseases “Prof. Dr. Matei Bals” Bucharest (flu, pneumococcal)Severe influenza cases, both in adult and pediatric population are managed in the Institute.

The Institute is also part in the national influenza surveillance system (Romania has a national sentinel type surveillance system for influenza).A dedicated hospital epidemiology unit contributes to the national influenza surveillance program.

• Head of Institution: Prof. Dr. Adrian Streinu-Cercel
• Dr. Anca Cristina Draganescu
• Assoc. Prof. Dr. Daniela Pitigoi

National Institute for Infectious Diseases “Prof. Dr. Matei Bals” Bucharest

partners serbia

Institute of Public Health of Vojvodina (Novi Sad, Serbia)


The Institute of public health (IPH) of Vojvodina have significant scientific and practical experience in the field of influenza and immunization that has been acquired in numerous studies. The IPH of Vojvodina is the leading state Institution for the communicable diseases surveillance (including influenza) that are envisaged for compulsory reporting in Vojvodina.

The World Health Organization (WHO) as the National Influenza Centre (NIC) has recognized the IPH of Vojvodina, Centre of virology, since 1953. NIC is part of the WHO Global Influenza Surveillance Network, with the principal task of continuous virologic surveillance of influenza virus activity in population of Vojvodina.

Snežana Medić, MD, PhD, Project Coordinator
Mioljub Ristić, MD, PhD, Province Coordinator

• Institute of Pulmonary Diseases of Vojvodina, Sremska Kamenica
• Clinic for internal Diseases of the Clinical Center of Vojvodina
• General hospital of Agnibilekro
• Clinic for Infectious Diseases of the Clinical Center of Vojvodina
• Institute for Health Care of Children and Youth of Vojvodina

The National Reference Laboratory for Influenza and other respiratory viruses (Argentina, Buenos Aires)


Since 1996 the National Reference Laboratory/WHO National Influenza Centre (NIC) of Argentina serves as a central repository for acute respiratory illness surveillance data.

The central hospital of the study is a health institution, where activities of prevention, treatment, diagnosis and rehabilitation are conducted, as well as teaching and research activities.

The identification of influenza and other respiratory viruses is conducted at the Respiratory Virus Laboratory, Virology Department, including the influenza subtyping, determination of the influenza B lineages and influenza A and B genomic characterization according to the protocol of a real time platform validated by the US Center for Disease Control and Prevention (CDC).

Elsa Baumeister, PhD, Project Director
Graciela Cabral, PhD, Project Coordinator

National Hospital “Prof Alejandro Posadas”

Hospital Edouard Herriot, Department of Hygiene, Epidemiology and Prevention (France, Lyon)


Surveillance of nosocomial influenza was set-up in Edouard Herriot hospital in 2004 to estimate the risk of hospital acquired-ILI for hospitalized patients in short-stay units, and to identify determinants associated with nosocomial Influenza infection. Determinants from the community (influenza incidence, vaccine coverage, etc.) and from the hospital (underlying diseases, two-bed rooms, vaccine coverage among HCW, etc.) are explored to describe and initiate preventive measures to avoid hospital outbreak of influenza.

Since 2012 the hospital is involved into the FluVac study. This is a case-control prospective study coordinated by the REIVAC (Réseau national d’investigation clinique en vaccinologie). The main objective of this study is to assess the effectiveness of influenza vaccine in hospitalized patients with laboratory-confirmed influenza.

Professor Philippe Vanhems

Hospital Edouard Herriot

partners ivorycoast

National Institute of Public Hygien (INHP), Côte d’Ivoire (Ivory Coast)


The national institute is a public health institution whose mission is the control of infectious diseases. As such, it includes an epidemiological surveillance unit that conducts research on influenza.

Daouda COULIBALY, Head of the Epidemiological Surveillance Unit

• University hospital of Treichville
• University hospital of Bouaké
• General hospital of Agnibilekro
• Yopougon Attié hospital


If you are interested in the network,
please contact us:

This email address is being protected from spambots. You need JavaScript enabled to view it.